This blog was created while Lisa (Siobhan) was recovering in the MGH ICU after neurosurgery. She had a 1.5″ diameter tumor removed from her cerebellum. I created this site because keeping people informed of her progress was becoming unmanageable using emails and phone calls.
The posts from Jan 12-18, 2012 were originally emails and have been re-posted here, with minor edits and the appropriate dates.
A lot of people know that Lisa goes by Siobhan. To keep things simple, I will refer to her as Lisa in all my posts. I am solely responsible for the content of this site and the posts. Lisa and I have kept intentionally ignorant of brain tumors so that we did not in some cosmic way cause one to happen. Since they occurred anyway, the learning curve has been steep, and I apologize upfront for any confusing or conflicting content.
Thank you all for your love, prayers, and support at this difficult time.
God bless – Scott
The Progression of Lisa’s disease
Click here to see an illustrated timeline of Lisa’s fight against breast cancer.
Lisa had Stage IV metastatic breast cancer. That means that her cancer started out in her breast and then spread to other parts of her body. The cancer in her lungs, is not lung cancer, its breast cancer that metastasized to her lungs.
Lisa was diagnosed with an aggressive breast cancer, HER2 Neu positive, in 2005.
Even with aggressive chemo-therapies, surgeries, and radiation treatments it spread to her bones, lungs, and lymph nodes by 2009.
On January 12, 2012, an MRI of her brain confirmed that it had metastasized to her brain, “The MRI of shows what we were worried about, there are a couple tumors there.”
In April, 2012, a biopsy of her parotid gland showed that it had also spread to there.
In May, 2012, Lisa began receiving T-DM1, a “super” herceptin, as part of a phase II clinical trial. T-DM1 worked for nine treatments, about six months, before her disease showed marked progression and she was dropped from the T-DM1 trial. (In February, 2012, the FDA approved T-DM1 for treatment of HER2-positive metastatic breast cancer. The trademark name is Kadcyla.)
In Dec, 2012, Lisa began receiving GDC-0032, as part of a phase I clinical trial.
June 2013: GDC-0032 worked well for Lisa and kept her disease from progressing. After nearly seven-28/day cycles, treatment was stopped due to her developing colitis a known side-effect of the drug.
June 27, 2013: Lisa was admitted to an in-home hospice program.
August 25, 2013: Lisa passed away.